InterK Peptide Therapeutics is a preclinical biotechnology company developing immune-boosting synthetic peptides to treat cancer, UV-induced skin damage, and to act as an alternative to opioid analgesics.
In the area of cancer immunotherapy InterK is currently undertaking a clinical study to evaluate the effect of its compounds on immune cells in patients with metastatic melanoma receiving checkpoint blockade therapy.
The goal is to determine whether InterK’s compounds may have benefit as a combinatorial therapeutic for patients with advanced cancers and whether a “peptide signature” exists prior to treatment that can identify patients who are likely to respond.
InterK’s immune-boosting compounds inhibit pain equivalent to morphine in neuropathic and inflammatory preclinical models. Their role in minimizing opioid addiction is currently being explored.
InterK’s immune-boosting compounds prevent UV-induced DNA damage, collagen breakdown and melanin production.
Influenza A Virus
InterK is currently evaluating the effect of its compounds in preclinical models of influenza A virus infection.